Clairity, Inc. | $43,000,000 | (Nov 14, 2025)
CoRun.ai | $3,500,000 | (Nov 14, 2025)
Park Loyalty | Undisclosed Amount | (Nov 14, 2025)
Actithera
Norway
- Oslo
- 09/07/2025
- Series A
- $75,500,000
Actithera is a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs). Founded in 2021 by drug discovery innovator Dr. Andreas Goutopoulos, and seed investors M Ventures, and Arkin Bio Ventures II, Actithera applies various molecular design strategies, including covalent-targeting and an isotope-agnostic philosophy to invent RLTs with significant differentiation and larger therapeutic windows. Headquartered in Oslo, Norway, and Cambridge, Massachusetts, Actithera is committed to advancing a differentiated pipeline addressing critical unmet needs in oncology.
- Industry Biotechnology Research
- Website https://actithera.com/
- LinkedIn https://www.linkedin.com/company/actithera/
Related People
Andreas GoutopoulosFounder
United States -
Boston, Massachusetts
Founder of Actithera, developing smarter radiopharmaceuticals to treat cancer more effectively and safely. Focused on turning chemistry and science into better outcomes for patients.
Carbon(US) | $60,000,000 | (Nov 14, 2025)
Big Rentals | $2,800,000 | (Nov 14, 2025)
Anzen Insurance | $16,000,000 | (Nov 14, 2025)
Beacon Biosignals | $86,000,000 | (Nov 14, 2025)
Fabric8Labs | $50,000,000 | (Nov 14, 2025)
Songscription | $5,000,000 | (Nov 14, 2025)
sunday (US) | $21,000,000 | (Nov 14, 2025)
Maybern | $50,000,000 | (Nov 14, 2025)